Market Closed -
Nasdaq
21:30:00 24/06/2024 BST
|
5-day change
|
1st Jan Change
|
0.9302
USD
|
+0.67%
|
|
+0.65%
|
-35.40%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
62.64
|
31.85
|
15.82
|
10.14
|
6.259
|
4.548
|
-
|
-
|
Enterprise Value (EV)
1 |
62.64
|
31.85
|
5.389
|
10.14
|
6.259
|
4.548
|
4.548
|
4.548
|
P/E ratio
|
-7.37
x
|
-4.09
x
|
-1.03
x
|
-0.82
x
|
-0.63
x
|
-0.49
x
|
-0.82
x
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-
|
-1,121,908
x
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-12,661,159
x
|
-
|
-1,308,549
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
405
|
537
|
959
|
1,300
|
4,346
|
4,889
|
-
|
-
|
Reference price
2 |
154.8
|
59.25
|
16.50
|
7.800
|
1.440
|
0.9302
|
0.9302
|
0.9302
|
Announcement Date
|
02/03/20
|
16/03/21
|
30/03/22
|
31/03/23
|
28/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-14.1
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-7.715
|
-7.302
|
-14.1
|
-11.07
|
-7.692
|
-11.8
|
-16
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-7.705
|
-7.213
|
-14.31
|
-11.37
|
-7.845
|
-11.8
|
-16
|
-
|
Net income
1 |
-7.705
|
-7.213
|
-14.31
|
-11.37
|
-7.845
|
-11.8
|
-16
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-21.00
|
-14.50
|
-16.00
|
-9.500
|
-2.300
|
-1.900
|
-1.140
|
-
|
Free Cash Flow
|
-4.947
|
-
|
-12.09
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
02/03/20
|
16/03/21
|
30/03/22
|
31/03/23
|
28/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-3.38
|
-2.661
|
-2.3
|
-2.684
|
-3.421
|
-2.193
|
-1.709
|
-2.093
|
-1.698
|
-2.054
|
-2.8
|
-3.1
|
-3.5
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-3.48
|
-2.572
|
-2.678
|
-2.644
|
-3.479
|
-2.184
|
-1.873
|
-2.087
|
-1.702
|
-2.041
|
-2.8
|
-3.1
|
-3.5
|
-
|
-
|
Net income
1 |
-3.48
|
-2.572
|
-2.678
|
-2.644
|
-3.479
|
-2.184
|
-1.873
|
-2.087
|
-1.702
|
-2.041
|
-2.8
|
-3.1
|
-3.5
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-3.500
|
-2.750
|
-2.250
|
-2.050
|
-2.720
|
-0.8800
|
-0.5700
|
-0.6000
|
-0.3100
|
-0.4600
|
-0.4700
|
-0.5000
|
-0.4700
|
-0.3600
|
-0.3100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/03/22
|
12/05/22
|
12/08/22
|
10/11/22
|
31/03/23
|
15/05/23
|
11/08/23
|
13/11/23
|
28/03/24
|
14/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
10.4
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-4.95
|
-
|
-12.1
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
02/03/20
|
16/03/21
|
30/03/22
|
31/03/23
|
28/03/24
|
-
|
-
|
-
|
Last Close Price
0.9302
USD Average target price
5.5
USD Spread / Average Target +491.27% Consensus |
1st Jan change
|
Capi.
|
---|
| -35.40% | 4.55M | | +52.70% | 801B | | +41.58% | 631B | | -4.86% | 359B | | +21.96% | 337B | | +11.47% | 305B | | +17.72% | 245B | | +4.46% | 231B | | +13.13% | 219B | | +10.46% | 171B |
Other Pharmaceuticals
|